

# SCIENTIFIC REPORTS



OPEN

## Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics Approach

Li Li<sup>1,6,\*</sup>, Ilana Greene<sup>2,\*</sup>, Benjamin Readhead<sup>1,6</sup>, Madhav C. Menon<sup>2</sup>, Brian A. Kidd<sup>1,6</sup>, Andrew V. Uzilov<sup>3</sup>, Chengguo Wei<sup>2</sup>, Nimrod Philippe<sup>2</sup>, Bernd Schroppe<sup>2,4</sup>, John Cijiang He<sup>2</sup>, Rong Chen<sup>3</sup>, Joel T. Dudley<sup>1,5,6,\*</sup> & Barbara Murphy<sup>2,\*</sup>

Received: 02 June 2016  
Accepted: 21 November 2016  
Published: 04 January 2017

Chronic allograft damage, defined by interstitial fibrosis and tubular atrophy (IF/TA), is a leading cause of allograft failure. Few effective therapeutic options are available to prevent the progression of IF/TA. We applied a meta-analysis approach on IF/TA molecular datasets in Gene Expression Omnibus to identify a robust 85-gene signature, which was used for computational drug repurposing analysis. Among the top ranked compounds predicted to be therapeutic for IF/TA were azathioprine, a drug to prevent acute rejection in renal transplantation, and kaempferol and esculetin, two drugs not previously described to have efficacy for IF/TA. We experimentally validated the anti-fibrosis effects of kaempferol and esculetin using renal tubular cells *in vitro* and *in vivo* in a mouse Unilateral Ureteric Obstruction (UUO) model. Kaempferol significantly attenuated TGF- $\beta$ 1-mediated profibrotic pathways *in vitro* and *in vivo*, while esculetin significantly inhibited Wnt/ $\beta$ -catenin pathway *in vitro* and *in vivo*. Histology confirmed significantly abrogated fibrosis by kaempferol and esculetin *in vivo*. We developed an integrative computational framework to identify kaempferol and esculetin as putatively novel therapies for IF/TA and provided experimental evidence for their therapeutic activities *in vitro* and *in vivo* using preclinical models. The findings suggest that both drugs might serve as therapeutic options for IF/TA.

Chronic allograft damage, represented by interstitial fibrosis and tubular atrophy in allografts (IF/TA) is the leading cause of allograft failure despite the improvement in immunosuppression therapies and short-term graft survival<sup>1–3</sup>. Natural history studies in allografts have shown that the rate of progression of IF/TA remains relatively constant, with limited improvements in slowing progressive deterioration of kidney function and extending graft survival<sup>4,5</sup>. Also, early chronic histological damage or kidney fibrosis was significantly associated with graft loss as an independent risk factor, even in the absence of progressive disease (e.g., antibody-mediated rejection or glomerulonephritis)<sup>6</sup>. Moreover, the global burden of early chronic histological damage within the first year after renal transplantation greatly affects the outcome of the allografts<sup>6</sup>. The extent of disease progression varies on presentation amongst renal transplant recipients, and evidence of a specific underlying etiology is usually lacking<sup>7,8</sup>. Experimental studies in animal models attempting to treat IF/TA demonstrate effects in mitigating renal fibrosis. However, these experimental interventions prove to be difficult to implement in clinical practice, and currently available treatments cannot effectively prevent or revert the progression of IF/TA and improve renal graft function<sup>9–12</sup>. Chronic Allograft Dysfunction Index (CADI) is a broader histologic assessment for fibrosis in protocol biopsies that consists of 6 histologic parameters: interstitial inflammation in non-fibrotic areas (ii), interstitial fibrosis (IF), mesangial matrix (mm), vascular intimal proliferation (cv), tubular atrophy (TA), and glomerulosclerosis (gs)<sup>13,14</sup>.

<sup>1</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 770 exington Ave., New York, NY 10065, USA. <sup>2</sup>Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. <sup>3</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1255 5th Avenue, New York, NY 10029, USA. <sup>4</sup>Section of Nephrology, University of Ulm, Albert-Einstein-Allee 23, Ulm, 89081 Germany. <sup>5</sup>Department of Health Policy and Research, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA. <sup>6</sup>Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai. \*These authors contributed equally to this work. Correspondence and requests for materials should be addressed to J.T.D. (email: Joel.dudley@mssm.edu) or B.M. (email: Barbara.murphy@mssm.edu)

The pathophysiology of IF/TA is incompletely understood. Notably, IF/TA is also encountered in native kidneys with progressive diseases irrespective of etiology, and associates with functional decline and the development end-stage renal failure. Further, IF/TA in both allograft and native kidneys appear to share common risk loci strongly suggesting common pathogenetic mechanisms involved in renal fibrosis<sup>15,16</sup>. Multiple etiological factors may culminate in a common phenotype of IF/TA through several stereotypic phases<sup>17,18</sup>. Early injury to the allograft occurs as a result of transplantation-related injury (from ischemia and reperfusion) and consequent non-allo-specific inflammation likely leading on to allospecific immune activation<sup>19</sup>. This phase is followed by an enhancement of fibrogenic responses, culminating in the final phase of matrix accumulation and evident tissue fibrosis and the pathologic picture of IF/TA<sup>20</sup>. In both native and allograft-kidneys, fibrogenic processes are driven by well-described pathways involving transforming growth factor (TGF)- $\beta$ , Wnt/ $\beta$ -catenin, NF $\kappa$ B, Notch, and other growth factors<sup>10,21–23</sup>. TGF- $\beta$  has been implicated in the pathogenesis of IF/TA<sup>24</sup> through its contribution to the development of EMT<sup>25–28</sup>, and via downstream *Smad* signaling<sup>11,29</sup>. Therefore, TGF- $\beta$ -signaling pathway may serve as a potential target for treating IF/TA in native and allograft kidneys<sup>20,30,31</sup>. TGF- $\beta$  is known to induce the expression of Wnt/ $\beta$ -catenin superfamily members and cross-talk with the Wnt/ $\beta$ -catenin, and has been described as a promising new target for the treatment of fibrosis<sup>10,22,16,32</sup>. Therefore, the TGF- $\beta$  and Wnt/ $\beta$ -catenin pathways are attractive therapeutic targets for the slowing or preventing the progression of chronic allograft damage<sup>11,21</sup>.

The growing body of data from molecular profiling studies of IF/TA offers new opportunities for drug and biomarker discovery. Past studies of fibrosis in allograft show that kidney allograft biopsy and peripheral blood exhibit identifiable coordinated expression changes at the mRNA level<sup>33–37</sup>. However, many of the existing studies are single-center studies with often limited sample sizes, and comparison between studies raises challenges due to the variability of microarray platform, patient sample, and experiment protocols<sup>38</sup>. In this study, we developed a computational framework for utilizing publicly available data sets obtained NCBI Gene Expression Omnibus (GEO). Specifically, we obtained gene expression (i.e., transcriptome) datasets deposited into GEO from 6 different transplant centers. Our approach entails a systematic integration of the of genomic data using a meta-analysis technique followed by a drug repositioning approach for identifying novel therapeutic agents and targets for IF/TA.


We hypothesized that a molecular signature derived from a meta-analysis of multi-center independent gene expression data sets would yield a more robust molecular descriptor of IF/TA, which would improve therapeutic discovery by a computational drug repurposing approach. We identified a robust common transcriptional response in IF/TA consisting of 85 significantly expressed genes in IF/TA vs. non-IF/TA identified across multiple studies. Then, building on our previous systematic drug repurposing work<sup>39</sup>, we compared these 85 IF/TA gene signatures to the reference drug expression signatures from the Connectivity Map (cMAP)<sup>40</sup> to infer possible therapeutic indications based on their expression. We identified two compounds, kaempferol and esculetin, that our method predicts will perturb the expression levels of the 85-gene signature specific to IF/TA in a therapeutic direction. We validated the therapeutic effects of these compounds using *in vitro* and *in vivo* models. We found that the two drugs independently exhibit anti-fibrotic effects in an experimental model of renal fibrosis. Further, we identified potential cellular pathways and transcriptional mechanisms that facilitate the therapeutic effects of these compounds in models of IF/TA. Our findings present evidence that our computational strategy can uncover new uses for drugs for IF/TA as well as highlight novel targets and pathways for development of IF/TA therapies.

## Results

**Meta-analysis of transplant datasets reveals known molecular mechanisms of IF/TA.** We obtained raw data for six high-throughput gene expression studies from both peripheral blood and biopsy samples of renal transplant patients, with biopsy-proven IF/TA defined by CADI or IF/TA scores (S. Table 1). We used the high CADI or moderated and severe IF/TA phenotypes reported from the corresponding studies to increase the signal and identify clinically significant IF/TA. The resulting data set contained a total of 275 samples from 3 different microarray platforms on 2 tissues after manually curating datasets. All probe sets were re-annotated to the most recent NCBI Entrez gene identifier (Gene ID) by AILUN (ref. 41, <http://ailun.ucsf.edu>) then mapped by Gene ID, yielding 23,762 unique common genes across six platforms. We then performed quantile-quantile normalization for all 6 datasets to compensate systematic technical variation for samples<sup>42</sup>.

To derive a consensus molecular signature of differentially expressed genes in IF/TA across multiple data sets, we applied two meta-analysis methods to the normalized data (See methods, Fig. 1). First, we calculated a meta-effect size for each gene, weighted by the variance in the effect size within each of the six studies. We identified 996 genes that were measured in at least 4 out of 6 datasets and were both up or down regulated in IF/TA with false discovery rate (FDR)  $\leq 5\%$ . Secondly, we calculated enrichment of meta-SAM q values ( $\leq 10\%$ ) by the Fisher Exact test to identify the genes significantly expressed in all 6 datasets. We identified 510 genes that were significantly expressed in IF/TA with at least 3 out of 6 datasets with  $P \leq 5\%$ . Based on two meta-analysis methods, we have identified a total of 85 overlapped genes significantly specific to IF/TA. Up and down-regulated genes show consistence in gene expression for the IF/TA and non-IF/TA samples across the 6 different datasets by heatmap (S. Figure 1A–F). Meta-effect size, meta-SAM q values, effect size for each dataset, and SAM q values for each dataset were shown in S. Table 2A.

We performed pathway and network analysis for the 85 genes using QIAGEN's Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, <http://www.qiagen.com/ingenuity>) and discovered that 75 genes (88%, 75/85) were involved in immune cell trafficking, inflammatory response, cell death and survival, and cellular growth and proliferation biological functions (Fig. 2). The genes include major histocompatibility complex class II, interleukins, chemokine receptors, toll-like receptors, and T cell receptors, which are well known to be involved in kidney injury<sup>43–48</sup>. Similarly, canonical pathways for the 85 genes were related to the immune response, including dendritic (DC) cells, T cells, B cells, natural killer (NK) cells, Toll-like receptor, and NF $\kappa$ B signaling pathway




**Figure 1.** Work Flow of Identifying the Drug Targets through Integrative Informatics Approach.

(S. Table 2B). Three molecules, *UBC*, *MYC*, and *CTNNB1*, were connected with the most nodes, and associated with Wnt/ $\beta$ -catenin signaling pathway. *BTRC*, which is up-regulated in IF/TA, binds *UBC* and increases transcriptional activity of human  $\beta$ -catenin (*CTNNB1*) protein (Fig. 2). Eight genes related to kidney toxicity, including kidney failure (*CASP1*, *FCGR2A*, *FCGR2B*, *TLR2*, *TLR4*,  $P = 0.003$ ), damage of renal tubule (*TLR2*, *TLR4*,  $P = 0.01$ ), proximal tubular toxicity (*CTSS*, *LYZ*, *SLC22A5*,  $P = 0.007$ ) and their expression across 6 datasets were not confounded by tissue types (Fig. 3A–H). The 85 genes are significantly enriched ( $10\times$  median intensity across all tissues; <http://www.BioGPS.org>)<sup>49,50</sup> in different blood cells, namely CD14+ Monocytes (25,  $P_{\text{adj}} = 2.25\text{E-}27$ ), CD19+ B cells (12,  $P_{\text{adj}} = 3.41\text{E-}11$ ), DC Cells (12,  $P_{\text{adj}} = 3.55\text{E-}10$ ), CD4+ T cells (10,  $P_{\text{adj}} = 3.21\text{E-}8$ ), CD8+ T cells (10,  $P_{\text{adj}} = 3.86\text{E-}8$ ), and CD56+ NK cells (8,  $P_{\text{adj}} = 3.23\text{E-}5$ ).

**Computational prediction and assessment of novel drugs for IF/TA.** We used the 85 IF/TA-specific genes to prioritize a library of 1,309 drug induced transcriptional profiles<sup>40</sup> according to their predicted ability to perturb genes in the IF/TA signature, thus deriving a therapeutic ranking score for each compound. Score significance was estimated by generating an empirical score distribution for connections between IF/TA and 1,000 permuted drug signatures (see Methods). Compounds predicted to induce a state that is negatively correlated with IF/TA, (negative therapeutic ranking score,  $P \leq 0.05$ ) were shortlisted for further analysis. Among the strongest therapeutic predictions for IF/TA was azathioprine (the 133<sup>rd</sup> rank, score =  $-0.53$ ,  $P = 0.04$ ), which is known to prevent acute rejection in renal transplantation<sup>51</sup> and treat pulmonary fibrosis<sup>52</sup> (S. Figure 2). We performed a literature review of the most highly ranked drugs, and excluded those with profiles that would be impediments to their clinical application in IF/TA, such as having severe neurological and psychiatric side effects (S. Table 3). We identified two drugs, kaempferol and esculetin, that had acceptable toxicity profiles and that were known to induce biological perturbations relevant to fibrosis. Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, the 85<sup>th</sup> rank, score =  $-0.57$ ,  $P = 0.018$ ), is a naturally occurring flavanol-type flavonoid and found in natural food such as fruits and vegetables<sup>53</sup>. It suppresses TGF- $\beta$ -triggered Epithelial to Mesenchymal Transition (EMT) a possible mechanism for the generation of myofibroblast that contribute to fibrosis, and myofibroblast formation with concomitant restoration of E-cadherin expression, expression reduction of N-cadherin and  $\alpha$ -SMA and ECM component deposition<sup>54</sup>. Additionally it has been used as a target for therapeutic strategies in preventing airway fibrotic diseases<sup>54</sup> and schistosoma egg-induced hepatic fibrosis<sup>55</sup>. The second compound, esculetin (6,7-dihydroxycoumarin, the 37<sup>th</sup> rank, score =  $-0.52$ ,  $P = 0.005$ ), is a naturally occurring plant coumarin derivative and antioxidant<sup>56</sup>. It has been reported to decrease fibrosis and glomerulosclerosis in diabetic nephropathy by inhibiting the PPAR $\gamma$ /TGF- $\beta$  pathway and reversing expression of *Bmp6* and *Mmp13*<sup>57</sup>. We show the key genes (from the 85 IF/TA genes) that represent the leading edge of the connectivity scores with kaempferol and esculetin in S. Figure 3. A complete list of significant compounds driven by 85 IF/TA genes was shown in S. Table 3.


Further, our analysis found that kaempferol and esculetin were likely to exhibit positive therapeutic effects in IF/TA beyond anti-fibrosis activity. As the 85 genes were derived from transplantation datasets and, likely



**Figure 2.** IPA regulatory network using 75 of the 85 genes specific to IF/TA. We used 85 significantly expressed genes by two meta-analysis methods as input to IPA to create a gene-gene interaction network. We chose the direct relationship option in the IPA to create the interaction networks, resulting in 75 genes. The gradient of the red and green represent the positive and negative meta-effect size respectively. We highlighted the IF/TA biological relevant molecules which were significantly associated with communication between innate and adaptive immune cells in green rectangle, Fc $\gamma$  receptor-mediated phagocytosis in macrophages and monocytes in blue rectangle, B cell development in red rectangle, T cell receptor signaling in dark red rectangle, dendritic cell maturation in orange rectangle, and natural killer cell signaling in yellow rectangle.

incorporated signatures of ongoing allo-responses, we investigated whether kaempferol and esuletin could have specific effects on immune cells. We applied a recent developed immune-cell specific drug repurposing approach<sup>58</sup> to evaluate putative immune modulatory actions of kaempferol and esuletin. Using this methodology we can identify specific immune cell subsets a drug may potentially influence. By comparing differences in immune cell signatures with transcriptional changes from drug treatment, we examined which specific immune cell subsets would be influenced by kaempferol or esuletin, and whether these interactions were likely to activate or suppress cells involved in an immune response to transplantation. This analysis predicted that esuletin would inhibit both adaptive and innate immune cells including CD4 T cells ( $P_{adj} = 9.76E-15$ ), CD8 T cells ( $P_{adj} = 3.68E-13$ ), dendritic (DC) cells ( $P_{adj} = 0.00015$ ), B cells ( $P_{adj} = 1.64E-4$ ), and natural killer (NK) cells ( $P_{adj} = 0.0015$ ). Similarly, we predicted that kaempferol inhibit DC cells ( $P_{adj} = 6.24E-6$ ), NK cell ( $P_{adj} = 3.18E-5$ ), and NKT cell ( $P_{adj} = 0.00035$ ) activation. These findings are consistent with the cell types enriched in the 85 gene meta-analysis signature for IF/TA, and suggest that the two drugs have a potential role in the suppression of deleterious immune response in IF/TA<sup>59</sup>. Thus, kaempferol and esuletin were considered as potential candidates for further validation because of their high therapeutic ranking score, lack of reported toxicity in humans, and scientific literature supporting their therapeutic effects in experimental settings similar to IF/TA (S. Figure 2, S. Table 3).

**Kaempferol and esuletin attenuate pro-fibrotic pathways *in vitro*.** We performed an analysis to identify the cellular pathways that were significantly perturbed by kaempferol and esuletin using Human kidney 2 (HK2) cell lines. Given kaempferol's inhibition of TGF- $\beta$  signaling in airway fibrosis<sup>54</sup>, we investigated whether kaempferol could also decrease the effects of TGF- $\beta$  signaling in renal tubular cells. HK2 cells were cultured in 0.5% nutrient medium with 1, 3, 5, 10, and 15  $\mu$ M kaempferol for 24 hours. TGF- $\beta$  (5 ng/ml) was added during the last 12-hours for gene expression studies. Recent data has shown *Snai1* to be a key downstream zinc finger transcriptional repressor essential to TGF- $\beta$  mediated EMT in renal tubular cells<sup>44,60</sup>. We observed that treatment with 10 and 15  $\mu$ M kaempferol significantly reduced the TGF- $\beta$ -mediated expression of *SNAI1* ( $N = 3$  in each condition,  $P = 0.045$  and  $0.014$ ), and correspondingly reversed the down regulation of *CDH1*, an epithelial cell marker known to be repressed by *SNAI1*<sup>61</sup> ( $N = 3$  in each condition,  $P = 0.045$ ) (Fig. 4A). Next we




**Figure 3.** 8 genes associated with kidney failure and tubular toxicity. Forest plots are presented as in 3(A–H) in 6 independent studies consisting of 275 kidney transplant samples. Meta effect size was in black diamond, and biopsy and peripheral blood samples were in red and blue respectively.

examined the phosphorylation of *SMAD3*, a central signaling event in the canonical TGF- $\beta$  pathway<sup>62,63</sup>. Human kidney 2 (HK2) cells were cultured with kaempferol as above, and then stimulated with TGF- $\beta$ 1 for 20 minutes. *SMAD3* phosphorylation was decreased when treated with 10 and 15  $\mu$ M kaempferol ( $N = 3$  in each condition,  $P = 0.0044$  and  $0.0096$  respectively) (Fig. 4B). Additionally, since kaempferol has previously been found to inhibit NF $\kappa$ B, a known mediator of inflammatory signaling<sup>64</sup>, we incidentally observed that 15  $\mu$ M kaempferol decreased the phosphorylation of NF $\kappa$ B P65 (P-P65) relative to total P65 in renal tubular cells ( $N = 3$  in each condition,  $P = 0.022$ , Fig. 4B). These data suggest that kaempferol has inhibitory effects on TGF- $\beta$  signaling in renal tubular cells.

Esculetin's inhibition of canonical Wnt signaling through direct binding to  $\beta$ -catenin has been previously established in human colon cancer cells<sup>65</sup>, thus, we examined the effect of esculetin on HK2 cells stimulated with Wnt agonist. HK2 cells were cultured in 0.5% nutrient medium with 10, 20, 40, 60, and 80  $\mu$ M esculetin for 16 hours, followed by 8 hours of Wnt agonist stimulation to examine transcriptional changes, and 36 hours of Wnt agonist stimulation to examine long-term alterations in protein abundance. After 36 hours of Wnt agonist stimulation, 60 and 80  $\mu$ M esculetin decreased the protein levels of *CCND1* ( $N = 3$  in each condition,  $P = 0.0087$  and  $0.0054$  respectively, Fig. 4C), a well-known target of Wnt signaling<sup>66</sup>. After 8 hours of exposure to Wnt agonist, 20–80  $\mu$ M esculetin decreased *CCND1* mRNA expression ( $N = 3$  in each condition,  $P = 0.021$ ,  $0.0007$ ,  $0.0002$ , and  $<0.0001$  respectively) and 40–80  $\mu$ M esculetin decreased *MYC* transcripts ( $N = 3$  in each condition,  $P = 0.046$ ,  $0.024$ , and  $0.0055$ ) (Fig. 4D). These data suggest inhibition of Wnt/ $\beta$ -Catenin signaling by esculetin in renal tubular cells.

Moreover, HK2 cell viability was not affected by either 1–15  $\mu$ M kaempferol or 10–80  $\mu$ M esculetin applied for 24 hours based on the trypan blue exclusion method (S. Figure 4A and B).


**Kaempferol and esculetin inhibit renal interstitial fibrosis *in vivo*.** We then evaluated renal fibrogenesis *in vivo* with kaempferol and esculetin in a mouse unilateral ureteric obstruction model (UUO), a model of renal interstitial fibrosis. Kaempferol or esculetin treated BALB-C mice were subjected to UUO surgery as described earlier<sup>16</sup>. Tissues were harvested on day 7 post UUO and analyzed for gene-expression, histology and immunohistochemistry (IHC). PBS/DMSO-treated mice were used as controls. *Snai1* was significantly over expressed in UUO samples compared with controls ( $n = 6$ ,  $P < 0.0001$ ), and there was no significant difference for controls when treated with kaempferol. We demonstrated that kaempferol significantly decreased the expression the key transcriptional factor *Snai1* ( $N = 5$ ,  $P = 0.038$ , Fig. 5A) compared with PBS/DMSO-treated mice ( $N = 6$ ), suggesting inhibition of TGF-signaling, *in vivo*. Further, phosphorylation of P65 was significantly inhibited by Western blot, in lysates from UUO-kidneys treated with kaempferol, compared to controls (Fig. 5B). Similarly, *cyclin d1* was significantly over expressed in UUO samples compared with controls ( $n = 5$ ,  $P < 0.0001$ ), and *cyclin d1* was significantly decreased in controls as well as UUO kidneys when treated with esculetin compared to vehicle ( $N = 6$ ,  $P = 0.0011$  for controls; and  $N = 5$ ,  $P = 0.0032$  for UUO, Fig. 5C), and a significant reduction in *cyclin*



**Figure 4. Validation of kaempferol and esculletin through TGF- $\beta$  and Wnt/ $\beta$ -catenin pathways respectively in HK2 cells. (A)** *SNAI1* and *CDH1* gene expression determined by RT-PCR (normalized to *GAPDH*) for cells treated with kaempferol (1–15  $\mu$ M) for 12 hours followed by 12 hours of kaempferol in the presence of TGF- $\beta$  1 (5 ng/ml). **(B)** Western blots and associated densitometries for P-P65, total P65, P-SMAD3, total SMAD3 and  $\beta$ -Actin for HK2 cells treated with kaempferol (1–15  $\mu$ M) for 16–24 hours followed by 20 minutes of kaempferol in the presence of TGF- $\beta$ 1 (5 ng/ml). Quantifications were shown next to western blots. **(C)** Western blot and associated densitometry for *CCND1* and  $\beta$ -Actin for HK2 cells treated with esculletin (10–80  $\mu$ M) for 16 hours followed by 36 hours of esculletin in the presence of Wnt-agonist (1.25  $\mu$ M). Quantifications were next to western blot. **(D)** *CCND1* and *MYC* gene expression determined by Q-PCR (normalized to *GAPDH*) for cells treated with esculletin (10–80  $\mu$ M) for 16 hours followed by 8 hours of esculletin in the presence of Wnt-agonist (1.25  $\mu$ M). N = 3 in each arm. Western blot experiments on (B) and (C) were run under the same experimental conditions. Data were represented in mean and standard error of the mean.

*d1* protein production (N = 5, P = 0.038) (Fig. 5D) compared with PBS/DMSO-treated mice (N = 5), thus lending further support to esculletin's inhibition of Wnt signaling as a potential mechanism of its anti-fibrotic effect. There was no significant difference for P-Smad3, total Smad3, P-P65 and total P65 between PBS/DMSO vs. PBS/DMSO treated with kaempferol. Similarly, there was no significant difference for Cyclin D1 for esculletin, suggesting neither drug has effects on controls samples (S. Figure 5).

UUO kidneys from mice treated with kaempferol had a significant reduction in interstitial collagens and renal fibrosis by picrosirius red staining (P = 0.0009, Fig. 6A,C), and *Collagen-1* production compared with controls by IHC (P < 0.0001, Fig. 6A,B). Similarly, mice treated with esculletin had a significant reduction in interstitial fibrosis by picrosirius red staining (P = 0.0011, Fig. 6A,C) and anti-collagen 1 IHC staining (P < 0.0001, Fig. 6A,B). These data support our computational inferences, and confirm our *in vitro* findings demonstrating the beneficial *in vivo* effects of Kaempferol and Esculetin on renal fibrogenesis.




**Figure 5. Kaempferol and esculletin inhibit pro-fibrotic mediators in 7 days UUO model.** (A) *Snail* gene expression of kaempferol treated mice (N = 5) compared with PBS/DMSO-treated mice (N = 6) in UUO model and controls. (B) Western blots in UUO model for *P-Smad3*, total *Smad3*, *P-p65*, total *p65*, and *GAPDH* between kaempferol treated mice (N = 3) and PBS/DMSO treated mice (N = 2). Quantifications were shown next to western blots. (C) *Cyclin D1* gene expression of esculletin treated mice (N = 5) compared with PBS/DMSO treated mice (N = 6) in UUO model and controls. (D) Western blots in UUO model for *Cyclin d1* and *GAPDH* between esculletin treated mice (N = 5) and PBS/DMSO treated mice (N = 6). Western blot experiments on (B) and (D) were run under the same experimental conditions. Quantifications were shown next to western blots. Data were represented in mean and standard error of the mean.

## Discussion

IF/TA is a progressive and irreversible process that represents the major barrier to long-term renal allograft survival. Despite increased efforts in therapeutic discovery, there remain unmet clinical needs for effective strategies to treat IF/TA. In this study, we aimed to identify novel therapeutic targets to potentially ameliorate IF/TA through an integrative computational framework. We hypothesized that a robust molecular signature from a meta-analysis of multi-center independent gene expression data sets integrated with a computational drug repurposing approach would suggest novel therapeutic targets for rational drug discovery and design.

Though several previous studies explored transcriptional patterns associated with IF/TA in renal transplantation, their small sample sizes limits their ability to capture the molecular heterogeneity of IF/TA<sup>16,33–37</sup>. Furthermore, experimental confounders, such as the variability of microarray platforms and experiment protocols in different centers, can confound the interpretation of transcriptional findings across studies. Our strategy employed a two-step meta-analysis of 275 biopsy and peripheral blood samples from publicly available microarray datasets. Additionally, we have performed similar statistical methods of SAM and effective size to identify significant gene list, then to identify the signified drugs from CMap for each of the 6 datasets. Interestingly, there are very few overlapped drugs across 4–5 datasets and none among all 6 datasets (S. Figure 6). Therefore, we proposed that meta-analysis of publicly available data from multiple centers can deliver a robust gene signature which implicitly accounts for the underlying molecular heterogeneity of IF/TA, the variability of the host response, differences in treatment protocols, and other clinical and sample confounding factors<sup>67</sup>. Our approach significantly increases sample size and ameliorates single study bias by integrating 6 independent datasets from 6 institutions. Our meta-analysis identified 85 genes that were associated with IF/TA. This meta-analysis signature was enriched for pathways and biological functions reflective of known IF/TA pathophysiology as well as potentially novel factors. We then sought to discover novel therapeutic relationships between drug compounds and IF/TA using a computational drug repurposing approach based on expression signatures of small molecule compounds<sup>40</sup>. We proposed that drugs that have a potentially therapeutic effect will be able to reverse the differential expression of the 85 IF/TA-specific gene set during drug exposure in a modeled cell line<sup>39</sup>. We selected two drugs for *in vitro* and *in vivo* validations, kaempferol and esculletin, two plant-derived compounds that were ranked at the top of the 1,309 compounds.

The therapeutic agents identified and experimentally validated in our study could form the basis of safer therapeutic strategies for IF/TA. Most patients still receive calcineurin inhibitor based immunosuppression protocols post kidney transplantation<sup>68</sup>. Studies have shown that the majority of patients receiving tacrolimus at 5 years post kidney transplantation develop CAN ( $\geq$  Banff grade I) and with evidence of calcineurin inhibition (CNI) nephrotoxicity<sup>19</sup>. CNI nephrotoxicity plays an important role in late histologic injury and ongoing decline in renal function<sup>19</sup>. Therefore, avoiding adverse side effects of immunosuppressive therapy, especially nephrotoxicity, is a primary goal in designing an effective approaches for the prevention of IF/TA. Kaempferol and esculletin could potentially be administered as part of the long-term immunosuppression protocol, creating a balance between decreasing interstitial fibrosis without increasing immunological risk. Recent studies have identified



**Figure 6. Kaempferol and esculetin reduce renal fibrosis in 7 days UUO model.** (A) Representative images of picrosirius red stain (*collagen 1* and *collagen 3*) and *collagen 1* IHC of renal cortex. (B) Quantification of *collagen 1* IHC of renal cortex between UUO kidney and control kidney with PBS/DMSO (N = 6) or kaempferol treatment (N = 5). (C) Quantification of Picrosirius red (*collagen 1* and *collagen 3*) stained renal cortex between UUO kidney and control kidney with PBS/DMSO (N = 6) or esculetin treatment (N = 5). Note: 10–15 random hpfs/animal, original magnification, x40. Data were represented in mean and standard error of the mean.

plant-derived compounds that are effective as adjuvant therapies in the treatment of chronic conditions such as chronic HCV infection. One such example is ladanein (BJ486K), a flavonoid related to kaempferol<sup>69,70</sup>.

We demonstrate here that kaempferol and esculetin abrogated profibrotic molecular processes *in vitro* and *in vivo*, and decrease renal interstitial fibrosis. From our data, kaempferol's anti-fibrotic effects are in part mediated by its effects on TGF- $\beta$  signaling pathway. However, further studies are needed to study the exact site of interaction between Kaempferol and TGF- $\beta$  signaling. While reduced phosphorylation of *smad3* suggests an effect on canonical-SMAD signaling, the incidental effects on P-P65 suggest a non-canonical pathway effect, whereas *Snail* can be induced in response to TGF- $\beta$  by both canonical and non-canonical downstream signals<sup>71</sup>. Indeed, *Snail*



is a widely implicated central transcription factor in EMT gene expression induced by TGF- $\beta$ /smad3 signaling in fibrosis models<sup>44,60,61,72</sup>. While kaempferol decreased NF $\kappa$ B activation *in vivo*, we did not see a significant difference in inflammatory genes known to be mediated by NF $\kappa$ B activation (data not shown). Esculetin's anti-fibrotic effects seemed to be mediated by its reduction of Wnt signaling due to its amelioration of *cyclin d1* gene expression and protein levels in the mouse UUO. *Cyclin d1* is a crucial regulator of Wnt-regulated organism development<sup>66</sup>. When Wnt binds its receptor,  $\beta$ -catenin is released to translocate from the cytoplasm to the nucleus and stimulates *cyclin d1* gene transcription<sup>73</sup>. This was further supported by esculetin's reduction of Wnt-induced gene expression and protein levels *in vitro* using Wnt-agonist stimulated HK2 cells.

The 85 genes specific to IF/TA were significantly enriched for T cells, B cells, monocytes, NK, and DC cells and signaling pathways were involved in communication between innate immune (DC and NK cells) and adaptive immune cells (B and T cells), B cell development, DC maturation, B/T/NK cell receptor signaling, as well as several macrophages related immune response pathways (S. Table 2B). Previous studies indicate that macrophages mediate endothelial cell cytotoxicity leading to loss of renal microvasculature<sup>74</sup>, are predictive of IF/TA development in an early biopsy<sup>75</sup>, and that M2-type macrophages promote the development of interstitial fibrosis in IF/TA<sup>76,77</sup>. These studies support that macrophages play a significant role for IF/TA<sup>9</sup>. Our findings also support previous reports that the high CADI genes were enriched in proliferation of T and B cells, NK cell activation, and DC cell migration<sup>34</sup>, as well as two tolerance (TOL) biomarker lists (TOL vs. CAN) where NK and DC cell types are enriched in both liver and kidney transplantation<sup>78,79</sup>. Interestingly, kaempferol and esculetin were predicted to antagonize activations of T, B, NK, and DC cells. This concordance illustrates the complex interplay with potential therapeutic drugs between innate and adaptive immune responses in IF/TA after renal transplantation<sup>80</sup>. The subtle inflammatory infiltrates in IF/TA are important to the scarring process and for ultimate graft outcome<sup>81</sup>. Importantly, our transcriptomic data supports the growing theory that immune cell types such as T, B cells<sup>82</sup>, NK cells<sup>83,84</sup>, dendritic cells<sup>85–87</sup> are involved in IF/TA and may be driving the immunological processes after transplantation, and possible therapeutic interventions such as kaempferol and esculetin could be applied to target these cell types. However, these predicted immune cell-specific inhibitory effects of kaempferol and esculetin cannot be confirmed or ruled out from our murine UUO model, a commonly used model for examining tubulointerstitial fibrosis<sup>88,89</sup>. While inflammation contributes to injury and fibrosis in this model, the abrogatory effects on fibrosis with kaempferol and esculetin observed here suggest a benefit that is independent of an allo-immune response and could indeed signal a wider potential role for these drugs in other chronic kidney diseases. Further studies using animal models of chronic allograft damage could specifically delineate the additional effects of these drugs on allo-immunity driven processes, although murine IF/TA models have suffered from lack of standardized technique and high complications<sup>90,91</sup>.

One potential limitation of our study is that it did not explore the entire space of therapeutic compounds. The current version of cMAP<sup>40</sup> contains only 1,309 compounds on more than 7,000 expression profiles representing profiling from culture cell lines. The total coverage of compounds and limited drug perturbation gene expression data limited the drug search space. However, the compounds represented in cMAP have been used to identify numerous other novel therapeutic indications for existing drugs<sup>39,92</sup>. Another option is to extend this approach to other small molecule signature libraries, such as the Library of Integrated Network-based Cellular Signatures (LINCS) (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70138>). This would allow evaluation of approximately 20,000 additional compounds, however these signatures are imputed from direct measurement of only 978 "Landmark" genes, rather than full microarray signatures used in the current study.

In conclusion, our current study is the first study of identifying novel therapeutic opportunities for IF/TA treatment through an integrative computational framework of transcriptome meta-analysis and drug repositioning approaches. We demonstrate that by expanding the sources of samples, tissue types, and various platforms from independent studies for IF/TA, we are able to identify a robust, biologically relevant, IF/TA-specific signature that can be useful for therapeutic repositioning. Kaempferol and esculetin have independently exhibited anti-fibrotic mechanisms in a model of renal fibrosis, and have abrogated cellular pathways and gene expressions involved in IF/TA and could be potentially used as novel adjuvant therapies that minimize side effects. Furthermore, our computational framework can be applied to address other unmet needs in transplantation, nephrology, and fibrosis.

## Materials and Methods

**Microarray datasets collection, preprocessing, and integration.** We obtained 5 kidney transplant microarray datasets from GEO and 1 in-house microarray dataset (S. Table 1). Each dataset was manually curated to select biopsy or peripheral blood samples from Homo sapiens organism. For each study, we used the clinical and phenotypic descriptors reported by the corresponding original studies. We selected IF/TA samples confirmed by protocol biopsy as follows: high CADI scores at 3 months (n = 1), 6 months (n = 3), and  $\geq 1$  year (n = 21) from Naesens study<sup>34</sup>; moderate and severe IF/TA (n = 22) at 1 year from Kurian study<sup>36</sup>; nonspecific IF/TA (n = 17) from Hayde study<sup>33</sup>; IF/TA II and III (n = 18)  $\geq 1$  year from Rodder study<sup>37</sup>; IF/TA and IF/TA+i (n = 40) at 1 year from Park study<sup>35</sup>; high CADI scores at 1 year (n = 6) from our in-house study (GSE74313). The human samples used in our study were approved by Institutional Review Board approval at Mount Sinai Hospital (05-1013), and all methods and analyses were conducted in accordance with this approval. Informed consent was obtained from all subjects used in this study. Stables, normal and low CADI samples with matched time points post-transplant in each study were served as non-IF/TA.

We performed quality assessment of the raw microarray datasets obtained from GEO. All probe sets on three different platforms (Affymetrix Human Genome U133 Plus 2.0, Affymetrix Human Exon 1.0 ST, and Affymetrix Human Gene 1.0 ST) were re-annotated to the most recent NCBI Entrez Gene Identifiers (Gene IDs) by ALLUN (ref. 41, <http://ailun.ucsf.edu>). We normalized each data set using quantile-quantile normalization<sup>42</sup>, and used Gene IDs to cross map genes among three different platforms.

**Microarray meta-analysis.** We analyzed the six microarray datasets using two different meta-analysis methods: (1). Combining the effect sizes across the studies (equation 1). (2). Combining SAM q values across the studies (equation 2) (Fig. 1). The first method estimated the effect size for each gene in each data set. We summarized the effect size using a fixed effect inverse-variance model. We combined the study-specific effect sizes for each gene into one meta-effect size ( $f_{meta}$ ) using a linear combination of effect sizes ( $f_i$ ) by weighting each effect size by the inverse of the variance ( $w_i$ ) in the corresponding study. It indicates that studies with less intra-study variation (noise) contribute more to the overall estimate of meta-effect size<sup>93</sup>. We then calculated the false discovery rate (FDR)<sup>94</sup> for multiple hypotheses testing for each gene (equation 1). We used the  $FDR \leq 5\%$  as cutoff for selecting significant genes. For the second meta-analysis method, we used Significance Analysis of Microarrays (SAM)<sup>95</sup> to identify the significantly expressed genes with q-value < 10% between IF/TA and non-IF/TA phenotypes in each study. Then, we performed the Fisher-Exact test for calculating the probability of obtaining the number of studies with the significant genes by the hypergeometric distribution (equation 2). We used  $p \leq 0.05$  as cutoff for selecting significant genes.

$$f_{meta} = \frac{f_1 w_1 + f_2 w_2 + f_3 w_3 + \dots + f_k w_k}{w_1 + w_2 + w_3 + \dots + w_k}; w_i = \frac{1}{var(f_i)} \quad (1)$$

$$p_i = \frac{\binom{a+b}{a} \binom{c+d}{c}}{\binom{n}{a+c}} = \frac{(a+b)!(c+d)!(a+c)!(b+d)!}{a!b!c!d!n!} \quad (2)$$

where  $a$  is the number of positive experiments for gene  $i$ ,  $b$  is sum of the number of positive experiments for all other genes,  $c$  is the number of negative experiments for gene  $i$ , and  $d$  is the number of negative experiments for all other genes.

We used Ingenuity Pathway Analysis (IPA, <http://www.ingenuity.com>, Redwood city, CA) to identify the significant signaling pathways for the overlapped genes from two meta-analyses. We chose  $-\log_{10}P > 1.3$  as a threshold for identifying significant pathways in IPA. We used BioGPS<sup>49,50</sup> to identify the blood cell types in which the overlapped genes were highly expressed. A gene was highly expressed in a blood cell type if its expression in a given blood cell type was greater than 10 times its median expression over all tissues. We used hypergeometric test to determine whether the proportion of the overlapped genes in each cell type was statistically significant or not. The P-values from hypergeometric test were corrected for multiple hypotheses using Benjamini-Hochberg correction.

**Drug repositioning approach.** We employed a computational drug repurposing approach to identify compounds predicted to ameliorate molecular states associated with IF/TA based on the concordance of drug-induced gene expression profiles from Connectivity Map (CMap)<sup>40</sup>. Each IF/TA signature was used to query CMap, a large library of drug induced transcriptional profiles<sup>40</sup>. We merged the 6,100 individual experiments into a single representative signature for the 1,309 unique small molecule compounds, according to the prototype-ranked list method<sup>96</sup>. For each unique compound, a modified Kolmogorov-Smirnov (KS) score was calculated<sup>40</sup>, summarizing the transcriptional relationship to the IF/TA signature, quantifying the tendency for those genes to be concordantly over- or under-expressed in the context of a given compound. Significance of individual scores was estimated by generating an empirical KS score distribution from the query network to 1,000 permuted drug signatures.

We hypothesized that if a IF/TA state is signified by a specific set of genome-wide transcriptional expression changes, and if exposure to a particular drug causes the reverse set of changes in a model cell line, then that drug has the potential to have a therapeutic effect on IF/TA<sup>39</sup>. We thus generated a ranked list of potential treatments for IF/TA from compounds predicted to induce an anti-correlated state to IF/TA ( $P \leq 0.05$ )<sup>39,97</sup> (Fig. 1).

We used Immune Pharmacology Map (IP-Map)<sup>98</sup>, a system-wide interaction map between drugs and immune cells by matching 1,309 drug perturbation profiles in the CMap<sup>40</sup> to 304 immune cell state changes that we curated from the Immunological Genome compendia (ImmGen)<sup>99</sup>, to evaluate the significance of our predicted drug-cell type interactions to potentially underline the affected immune cell types. We generated random drug perturbation profiles for each compound and repeated the analysis 1,000 times for each immune cell state change. We used the generalized Pareto distribution to model the P-value distribution and calculated the extreme P-values calculation based on the distribution of permutation scores<sup>100</sup>. We reported adjusted P-values by performing the Benjamini Hochberg multi-hypothesis testing.

**Cell culture.** Human kidney 2 (HK2) cells, which are immortalized proximal tubular epithelial cell (PTC) lines from normal adult human kidney, were cultured in RPMI-1640 medium (Corning). Upon reaching approximately 80% confluence, they were treated with indicated concentrations of kaempferol (EMD Millipore<sup>®</sup>), esculetin (Sigma<sup>®</sup>), or vehicle (0.15% DMSO for kaempferol and 0.5% DMSO for esculetin) in 0.5% nutrient medium. Cells were subsequently treated with 5 ng/ml TGF- $\beta$ 1 R&D Biosystems), 1.25  $\mu$ M Wnt agonist AG-L-67051 (Santa Cruz Biotech), or respective vehicle at the indicated times. We assessed cell viability with kaempferol or esculetin treatment after 24 hours with Trypan Blue (MP Biomedicals LLC) using standard protocol<sup>101</sup>.

**Western blot.** Cells were lysed using a 1% Triton lysis buffer with added protease, phosphorylation, and phosphatase inhibitors. Protein extracts were resolved using 8–10% Tris-glycine SDS-Polyacrylamide gels. The following antibodies (Cell Signaling) were used to detect proteins of interest: *anti-cyclin-d1*, *anti-P-smad3*,

*anti-total smad3, anti-phospho-P65, anti-total P-65, anti-β-actin, and anti-GAPDH*. Indicated bands were quantified using Image-J or Image Studio Lite<sup>102,103</sup>.

**Real Time PCR.** RNA was extracted using TRIzol Reagent (Life Technologies) and reversed transcribed using the Superscript III First-Strand Synthesis System (Life Technologies) following standard protocols. Real Time PCR (Applied Biosystems 7500) with the indicated primers was used to generate amplification curves that were analyzed using the  $\Delta\Delta CT$  method with *GAPDH* as a house-keeping gene and universal RNA (human universal RNA; Agilent Technologies) as a control. Primer sequences used in PCR are provided in S. Table 4.

**Fibrotic mouse model.** We used mouse unilateral ureteric obstruction (UUO) model to study the development of renal interstitial fibrosis. We obtained the *Balb/c* mice from Jackson Laboratory (Accession number: 000651)<sup>89</sup>. We followed the NIH Guide for the Care and Use of Laboratory Animals, and all methods and analyses were conducted in accordance with this guide. Eight week-old male *Balb/c* mice were administered 10 mg/kg/day of kaempferol (N = 5) or esculetin (N = 5) dissolved in 2.5% dimethylsulfoxide (DMSO) in Phosphate-buffered saline (PBS) beginning 2 days prior to undergoing UUO, and continued daily until the mice were sacrificed at 7 days post-UUO. Doses and modes of administration for the two compounds were chosen based on published literature<sup>104,105</sup>. Control mice were administered 2.5% DMSO in PBS (n = 6). Prior to the UUO, mice were anesthetized with an i.p. injection of 100 mg/kg ketamine and 16 mg/kg xylazine in PBS. 5–0 silk was used to completely ligate the left ureter 0.5 cm distal to the kidney with a total procedure time of 35–45 minutes. At 7 days post-UUO, the mice were perfused with PBS and tissue samples from the UUO kidney and contralateral kidney were collected for histology, RT-PCR, and Western Blot analysis.

**Histological evaluation.** Kidney tissue was immersed in formalin followed by paraffin fixation on slides performed by the Biorepository and Pathology CORE facility at Mount Sinai. Slides were then deparaffinized and subjected to immunohistochemistry (IHC) using anti-collagen 1 (Southern Biotech, 1:50) or picrosirius red stain (Abcam) using anti-collagen 1 and anti-collagen 3. IHC was performed using the Vectastain ABC avidin-biotin kit and developed using DAB substrate (Vector Laboratories). Stained sections were visualized using the Zeiss Axioplan 2 microscope, and 10–15 randomly selected high-power fields (hpf; original magnification x40) of the renal cortex were used to quantify the percentage of Picrosirius red stain or *COL1A1* (collagen 1) using Image J<sup>102,103</sup>.

All experimental protocols used in our study were approved by Icahn School of Medicine at Mount Sinai. We performed ANOVA for multiple comparisons and two-tailed T-test for unpaired comparisons with  $P \leq 0.05$  as significant level for experimental validation. Mean  $\pm$  standard error of mean was reported for quantification results. All statistics were computed by R 2.15.1<sup>106</sup>.

## References

- Meier-Kriesche, H. U., Schold, J. D. & Kaplan, B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **4**, 1289–1295, doi: 10.1111/j.1600-6143.2004.00515.x (2004).
- Pascual, M., Theruvath, T., Kawai, T., Tolkooff-Rubin, N. & Cosimi, A. B. Strategies to improve long-term outcomes after renal transplantation. *The New England journal of medicine* **346**, 580–590, doi: 10.1056/NEJMra011295 (2002).
- Hariharan, S., Alexander, J. W., Schroeder, T. J. & First, M. R. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival. *Clinical transplantation* **10**, 538–541 (1996).
- Nankivell, B. J. & Alexander, S. I. Rejection of the kidney allograft. *The New England journal of medicine* **363**, 1451–1462, doi: 10.1056/NEJMra0902927 (2010).
- Weir, M. R. & Wali, R. K. Minimizing the risk of chronic allograft nephropathy. *Transplantation* **87**, S14–18, doi: 10.1097/TP.0b013e3181a079c0 (2009).
- Naesens, M. *et al.* Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **13**, 86–99, doi: 10.1111/j.1600-6143.2012.04304.x (2013).
- Sis, B. *et al.* Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **10**, 464–471, doi: 10.1111/j.1600-6143.2009.02987.x (2010).
- Solez, K. *et al.* Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **7**, 518–526, doi: 10.1111/j.1600-6143.2006.01688.x (2007).
- Li, X. & Zhuang, S. Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation. *Fibrogenesis & tissue repair* **7**, 15, doi: 10.1186/1755-1536-7-15 (2014).
- Chuang, P. Y., Menon, M. C. & He, J. C. Molecular targets for treatment of kidney fibrosis. *Journal of molecular medicine* **91**, 549–559, doi: 10.1007/s00109-012-0983-z (2013).
- Shihab, F. S. Do we have a pill for renal fibrosis? *Clinical journal of the American Society of Nephrology: CJASN* **2**, 876–878, doi: 10.2215/CJN.02660707 (2007).
- Liu, Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. *Kidney international* **69**, 213–217, doi: 10.1038/sj.ki.5000054 (2006).
- Yilmaz, S. *et al.* Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies. *Journal of the American Society of Nephrology: JASN* **14**, 773–779 (2003).
- Isoniemi, H., Taskinen, E. & Hayry, P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. *Transplantation* **58**, 1195–1198 (1994).
- Freedman, B. I. *et al.* APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. *Transplantation* **100**, 194–202, doi: 10.1097/TP.0000000000000969 (2016).
- Menon, M. C. *et al.* Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. *The Journal of clinical investigation* **125**, 208–221, doi: 10.1172/JCI76902 (2015).
- Shrestha, B. M. & Haylor, J. Biological pathways and potential targets for prevention and therapy of chronic allograft nephropathy. *BioMed research international* **2014**, 482438, doi: 10.1155/2014/482438 (2014).
- Paul, L. C. Pathogenesis of chronic allograft nephropathy. *Current opinion in nephrology and hypertension* **7**, 635–637 (1998).

19. Nankivell, B. J. *et al.* The natural history of chronic allograft nephropathy. *The New England journal of medicine* **349**, 2326–2333, doi: 10.1056/NEJMoa020009 (2003).
20. Mannon, R. B. Therapeutic targets in the treatment of allograft fibrosis. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **6**, 867–875, doi: 10.1111/j.1600-6143.2006.01261.x (2006).
21. Guo, Y., Xiao, L., Sun, L. & Liu, F. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. *Physiological research/Academia Scientiarum Bohemoslovaca* **61**, 337–346 (2012).
22. He, W. *et al.* Wnt/beta-catenin signaling promotes renal interstitial fibrosis. *Journal of the American Society of Nephrology: JASN* **20**, 765–776, doi: 10.1681/ASN.2008060566 (2009).
23. Bielez, B. *et al.* Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. *The Journal of clinical investigation* **120**, 4040–4054, doi: 10.1172/JCI43025 (2010).
24. Campistol, J. M., Inigo, P., Larios, S., Bescos, M. & Oppenheimer, F. Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy. *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association* **16** Suppl 1, 114–116 (2001).
25. Robertson, H., Ali, S., McDonnell, B. J., Burt, A. D. & Kirby, J. A. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. *Journal of the American Society of Nephrology: JASN* **15**, 390–397 (2004).
26. Schnaper, H. W., Hayashida, T., Hubchak, S. C. & Poncelet, A. C. TGF-beta signal transduction and mesangial cell fibrogenesis. *American journal of physiology. Renal physiology* **284**, F243–252, doi: 10.1152/ajprenal.00300.2002 (2003).
27. Strutz, F. *et al.* Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. *Kidney international* **61**, 1714–1728, doi: 10.1046/j.1523-1755.2002.00333.x (2002).
28. Zeisberg, M. *et al.* Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. *The American journal of pathology* **159**, 1313–1321, doi: 10.1016/S0002-9440(10)62518-7 (2001).
29. Carroll, T. J., Park, J. S., Hayashi, S., Majumdar, A. & McMahon, A. P. Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. *Developmental cell* **9**, 283–292, doi: 10.1016/j.devcel.2005.05.016 (2005).
30. Dasch, J. R., Pace, D. R., Waegell, W., Inenaga, D. & Ellingsworth, L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. *Journal of immunology* **142**, 1536–1541 (1989).
31. Guan, Q. *et al.* Reduction of chronic rejection of renal allografts by anti-transforming growth factor-beta antibody therapy in a rat model. *American journal of physiology. Renal physiology* **305**, F199–207, doi: 10.1152/ajprenal.00665.2012 (2013).
32. Iglesias, D. M. *et al.* Canonical WNT signaling during kidney development. *American journal of physiology. Renal physiology* **293**, F494–500, doi: 10.1152/ajprenal.00416.2006 (2007).
33. Hayde, N. *et al.* The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy. *Clinical journal of the American Society of Nephrology: CJASN* **8**, 2141–2148, doi: 10.2215/CJN.04240413 (2013).
34. Naesens, M. *et al.* Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. *Kidney international* **80**, 1364–1376, doi: 10.1038/ki.2011.245 (2011).
35. Park, W. D., Griffin, M. D., Cornell, L. D., Cosio, F. G. & Stegall, M. D. Fibrosis with inflammation at one year predicts transplant functional decline. *Journal of the American Society of Nephrology: JASN* **21**, 1987–1997, doi: 10.1681/ASN.2010010049 (2010).
36. Kurian, S. M. *et al.* Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. *PLoS one* **4**, e6212, doi: 10.1371/journal.pone.0006212 (2009).
37. Rodder, S. *et al.* Renal allografts with IF/TA display distinct expression profiles of metzincins and related genes. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **9**, 517–526, doi: 10.1111/j.1600-6143.2008.02512.x (2009).
38. Dudley, J. T., Tibshirani, R., Deshpande, T. & Butte, A. J. Disease signatures are robust across tissues and experiments. *Mol Syst Biol* **5**, 307, doi: 10.1038/msb.2009.66 (2009).
39. Sirota, M. *et al.* Discovery and preclinical validation of drug indications using compendia of public gene expression data. *Science translational medicine* **3**, 96ra77, doi: 10.1126/scitranslmed.3001318 (2011).
40. Lamb, J. *et al.* The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* **313**, 1929–1935, doi: 10.1126/science.1132939 (2006).
41. Chen, R., Li, L. & Butte, A. J. AILUN: reannotating gene expression data automatically. *Nature methods* **4**, 879, doi: 10.1038/nmeth1107-879 (2007).
42. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinformatics* **19**, 185–193 (2003).
43. Yiu, W. H., Lin, M. & Tang, S. C. Toll-like receptor activation: from renal inflammation to fibrosis. *Kidney international supplements* **4**, 20–25, doi: 10.1038/kisup.2014.5 (2014).
44. Lovisa, S. *et al.* Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. *Nature medicine* **21**, 998–1009, doi: 10.1038/nm.3902 (2015).
45. Hsieh, P. F. *et al.* The role of IL-7 in renal proximal tubule epithelial cells fibrosis. *Molecular immunology* **50**, 74–82, doi: 10.1016/j.molimm.2011.12.004 (2012).
46. Kitagawa, K. *et al.* Blockade of CCR2 ameliorates progressive fibrosis in kidney. *The American journal of pathology* **165**, 237–246, doi: 10.1016/S0002-9440(10)63292-0 (2004).
47. Mannon, R. B. *et al.* Chronic rejection of mouse kidney allografts. *Kidney international* **55**, 1935–1944, doi: 10.1046/j.1523-1755.1999.00423.x (1999).
48. Lonemann, G. *et al.* Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. *Kidney international* **47**, 837–844 (1995).
49. Su, A. I. *et al.* A gene atlas of the mouse and human protein-encoding transcriptomes. *Proceedings of the National Academy of Sciences of the United States of America* **101**, 6062–6067, doi: 10.1073/pnas.0400782101 (2004).
50. Wu, C. *et al.* BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. *Genome biology* **10**, R130, doi: 10.1186/gb-2009-10-11-r130 (2009).
51. Bergan, S. *et al.* Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. *Transplantation* **66**, 334–339 (1998).
52. Izumi, S., Iikura, M. & Hirano, S. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *The New England journal of medicine* **367**, 870; author reply 870–871, doi: 10.1056/NEJMc1207471#SA3 (2012).
53. Miesan, K. H. & Mohamed, S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. *Journal of agricultural and food chemistry* **49**, 3106–3112 (2001).
54. Gong, J. H. *et al.* Inhibition of airway epithelial-to-mesenchymal transition and fibrosis by kaempferol in endotoxin-induced epithelial cells and ovalbumin-sensitized mice. *Laboratory investigation; a journal of technical methods and pathology* **94**, 297–308, doi: 10.1038/labinvest.2013.137 (2014).
55. Zhou, Y. *et al.* Preliminary exploration on anti-fibrosis effect of kaempferol in mice with schistosoma japonicum infection. *Eur J Inflamm.* **11**, 161–168 (2013).

56. Potapovich, M. V., Metelitsa, D. I. & Shadyro, O. I. Antioxidant activity of hydroxy derivatives of coumarin. *Prikladnaia biokhimiia i mikrobiologiia* **48**, 282–288 (2012).
57. Surte, V. M., Gupta, J. & Tikoo, K. Esculetin induced changes in Mmp13 and Bmp6 gene expression and histone H3 modifications attenuate development of glomerulosclerosis in diabetic rats. *Journal of molecular endocrinology* **46**, 245–254, doi: 10.1530/JME-10-0154 (2011).
58. Kidd, B. A. *et al.* Mapping the effects of drugs on the immune system. *Nat Biotechnol* **34**, 47–54, doi: 10.1038/nbt.3367 (2016).
59. Schreiner, G. F., Harris, K. P., Purkerson, M. L. & Klahr, S. Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney. *Kidney international* **34**, 487–493 (1988).
60. Grande, M. T. *et al.* Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. *Nature medicine* **21**, 989–997, doi: 10.1038/nm.3901 (2015).
61. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. *Nature reviews. Molecular cell biology* **15**, 178–196, doi: 10.1038/nrm3758 (2014).
62. Meng, X. M., Tang, P. M., Li, J. & Lan, H. Y. TGF-beta/Smad signaling in renal fibrosis. *Frontiers in physiology* **6**, 82, doi: 10.3389/fphys.2015.00082 (2015).
63. Guido, W., Tong, L. & Spear, P. D. Afferent bases of spatial- and temporal-frequency processing by neurons in the cat's posteromedial lateral suprasylvian cortex: effects of removing areas 17, 18, and 19. *Journal of neurophysiology* **64**, 1636–1651 (1990).
64. Cao, R., Fu, K., Lv, X., Li, W. & Zhang, N. Protective effects of kaempferol on lipopolysaccharide-induced mastitis in mice. *Inflammation* **37**, 1453–1458, doi: 10.1007/s10753-014-9870-9 (2014).
65. Lee, S. Y. *et al.* Esculetin suppresses proliferation of human colon cancer cells by directly targeting beta-catenin. *Cancer prevention research* **6**, 1356–1364, doi: 10.1158/1940-6207.CAPR-13-0241 (2013).
66. Pal, R. & Khanna, A. Role of smad- and wnt-dependent pathways in embryonic cardiac development. *Stem Cells Dev* **15**, 29–39, doi: 10.1089/scd.2006.15.29 (2006).
67. Khatri, P. *et al.* A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. *J Exp Med* **210**, 2205–2221, doi: 10.1084/jem.20122709 (2013).
68. Sieber, M. & Baumgrass, R. Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506? *Cell communication and signaling: CCS* **7**, 25, doi: 10.1186/1478-811X-7-25 (2009).
69. Farahani, M. S., Bahramsoltani, R., Farzaei, M. H., Abdollahi, M. & Rahimi, R. Plant-derived natural medicines for the management of depression: an overview of mechanisms of action. *Reviews in the neurosciences* **26**, 305–321, doi: 10.1515/revneuro-2014-0058 (2015).
70. Haid, S. *et al.* A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. *Gastroenterology* **143**, 213–222 e215, doi: 10.1053/j.gastro.2012.03.036 (2012).
71. Aomatsu, K. *et al.* TGF-beta induces sustained upregulation of SNAI1 and SNAI2 through Smad and non-Smad pathways in a human corneal epithelial cell line. *Invest Ophthalmol Vis Sci* **52**, 2437–2443, doi: 10.1167/iovs.10-5635 (2011).
72. Sato, M., Muragaki, Y., Saika, S., Roberts, A. B. & Ooshima, A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. *The Journal of clinical investigation* **112**, 1486–1494, doi: 10.1172/JCI19270 (2003).
73. Tetsu, O. & McCormick, F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature* **398**, 422–426, doi: 10.1038/18884 (1999).
74. Qi, F. *et al.* Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation. *Transplantation* **86**, 1267–1274, doi: 10.1097/TP.0b013e318188d433 (2008).
75. Pilmore, H. L., Painter, D. M., Bishop, G. A., McCaughan, G. W. & Eris, J. M. Early up-regulation of macrophages and myofibroblasts: a new marker for development of chronic renal allograft rejection. *Transplantation* **69**, 2658–2662 (2000).
76. Mannon, R. B. Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders? *Current opinion in organ transplantation* **17**, 20–25, doi: 10.1097/MOT.0b013e32834ee5b6 (2012).
77. Menon, M. C., Keung, K. L., Murphy, B. & O'Connell, P. J. The Use of Genomics and Pathway Analysis in Our Understanding and Prediction of Clinical Renal Transplant Injury. *Transplantation*, doi: 10.1097/TP.0000000000000943 (2015).
78. Roedder, S. *et al.* A Three-Gene Assay for Monitoring Immune Quiescence in Kidney Transplantation. *Journal of the American Society of Nephrology: JASN* **26**, 2042–2053, doi: 10.1681/ASN.2013111239 (2015).
79. Li, L. *et al.* A common peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver transplantation. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **12**, 1218–1228, doi: 10.1111/j.1600-6143.2011.03928.x (2012).
80. Kim, I. K., Bedi, D. S., Denecke, C., Ge, X. & Tullius, S. G. Impact of innate and adaptive immunity on rejection and tolerance. *Transplantation* **86**, 889–894, doi: 10.1097/TP.0b013e318186ac4a (2008).
81. Moreso, F. *et al.* Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **6**, 747–752, doi: 10.1111/j.1600-6143.2005.01230.x (2006).
82. Porcheray, F. *et al.* B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **9**, 2126–2135, doi: 10.1111/j.1600-6143.2009.02738.x (2009).
83. van der Touw, W. & Bromberg, J. S. Natural killer cells and the immune response in solid organ transplantation. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **10**, 1354–1358, doi: 10.1111/j.1600-6143.2010.03086.x (2010).
84. Beilke, J. N. & Gill, R. G. Frontiers in nephrology: the varied faces of natural killer cells in transplantation—contributions to both allograft immunity and tolerance. *Journal of the American Society of Nephrology: JASN* **18**, 2262–2267, doi: 10.1681/ASN.2007040423 (2007).
85. Thomson, A. W. Tolerogenic dendritic cells: all present and correct? *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **10**, 214–219, doi: 10.1111/j.1600-6143.2009.02955.x (2010).
86. Colvin, B. L., Matta, B. M. & Thomson, A. W. Dendritic cells and chemokine-directed migration in transplantation: where are we headed? *Clinics in laboratory medicine* **28**, 375–384, v, doi: 10.1016/j.cl.2008.07.003 (2008).
87. Steinman, R. M. & Banchereau, J. Taking dendritic cells into medicine. *Nature* **449**, 419–426, doi: 10.1038/nature06175 (2007).
88. Yang, H. C., Zuo, Y. & Fogo, A. B. Models of chronic kidney disease. *Drug discovery today. Disease models* **7**, 13–19, doi: 10.1016/j.ddmod.2010.08.002 (2010).
89. Chevalier, R. L., Forbes, M. S. & Thornhill, B. A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. *Kidney international* **75**, 1145–1152, doi: 10.1038/ki.2009.86 (2009).
90. Plenter, R., Jain, S., Ruller, C. M., Nydam, T. L. & Jani, A. H. Murine Kidney Transplant Technique. *J Vis Exp*, doi: 10.3791/52848 (2015).
91. Plenter, R. J., Jain, S., Nydam, T. L. & Jani, A. H. Revised Arterial Anastomosis for Improving Murine Kidney Transplant Outcomes. *J Invest Surg* **28**, 208–214, doi: 10.3109/08941939.2014.1002641 (2015).

92. Hu, G. & Agarwal, P. Human disease–drug network based on genomic expression profiles. *PLoS one* **4**, e6536, doi: 10.1371/journal.pone.0006536 (2009).
93. Morgan, A. A., Khatri, P., Jones, R. H., Sarwal, M. M. & Butte, A. J. Comparison of multiplex meta analysis techniques for understanding the acute rejection of solid organ transplants. *BMC bioinformatics* **11** Suppl 9, S6, doi: 10.1186/1471-2105-11-S9-S6 (2010).
94. Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. *Proceedings of the National Academy of Sciences of the United States of America* **100**, 9440–9445, doi: 10.1073/pnas.1530509100 (2003).
95. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. *Proceedings of the National Academy of Sciences of the United States of America* **98**, 5116–5121, doi: 10.1073/pnas.091062498 (2001).
96. Iorio, F. *et al.* Discovery of drug mode of action and drug repositioning from transcriptional responses. *Proceedings of the National Academy of Sciences of the United States of America* **107**, 14621–14626, doi: 10.1073/pnas.1000138107 (2010).
97. Dudley, J. T. *et al.* Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. *Science translational medicine* **3**, 96ra76, doi: 10.1126/scitranslmed.3002648 (2011).
98. Kidd, B. A. *et al.* Mapping the effects of drugs on the immune system. *Nature Biotechnology* In press (2015).
99. Heng, T. S., Painter, M. W. & Immunological Genome Project, C. The Immunological Genome Project: networks of gene expression in immune cells. *Nature immunology* **9**, 1091–1094, doi: 10.1038/ni1008-1091 (2008).
100. Knijnenburg, T. A., Wessels, L. F., Reinders, M. J. & Shmulevich, I. Fewer permutations, more accurate P-values. *Bioinformatics* **25**, i161–168, doi: 10.1093/bioinformatics/btp211 (2009).
101. Butler, M. & Spearman, M. Cell Counting and Viability Measurements. *Animal Cell Biotechnology* **24**, 205–222 (2007).
102. Collins, T. J. ImageJ for microscopy. *BioTechniques* **43**, 25–30 (2007).
103. Girish, V. & Vijayalakshmi, A. Affordable image analysis using NIH Image/ImageJ. *Indian journal of cancer* **41**, 47 (2004).
104. Pan, S. L. *et al.* Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats. *Biochemical pharmacology* **65**, 1897–1905 (2003).
105. Okamoto, I. *et al.* The flavonoid Kaempferol suppresses the graft-versus-host reaction by inhibiting type 1 cytokine production and CD8+ T cell engraftment. *Clinical immunology* **103**, 132–144, doi: 10.1006/clim.2001.5187 (2002).
106. Ihaka, R. & Gentleman, R. R. A language for data analysis and graphics. *Journal of Computational and Graphical Statistics* **5**, 299–314 (1996).

## Acknowledgements

We thank Dr. Riccardo Miotto and IT group for Linux cluster computing and database support; Mrs Caixia Xi for clinical database maintenance, and Drs Zichen Wang, Karen Keung, Weijia Zhang's discussion. This study was supported by funding from the NIDDK (R01DK098242) and NCI (U54CA189201) to J.T.D.; NIH (UO1 AI070107-01) to B.M.; AHA15SDG25870018 to M.C.M. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Author Contributions

Conceived and designed the study: L.L., J.D. and B.M. Performed the meta-analysis: L.L. Performed experiments of Q-PCR, western blot, HK2 and UUO model: I.G., M.C.M., C.W. and N.P. Performed drug repositioning analysis: B.R. Performed IP-Map analysis: B.K. Perform other statistical analysis: L.L. and I.G. Contributed annotation tools: A.Z. and R.C. Contributed sample collection: B.S. Wrote the paper: L.L., I.G., B.R. and M.C.M. Edited the paper: L.L., I.G., B.R., J.D., M.C.M., C.H. and B.M.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** J. D. owns equity in NuMedii Inc. and has received consulting fees or honoraria from Janssen Pharmaceuticals, GlaxoSmithKline, AstraZeneca and LAM Therapeutics. The other authors have declared that no conflict of interest exists.

**How to cite this article:** Li, L. *et al.* Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics Approach. *Sci. Rep.* **7**, 39487; doi: 10.1038/srep39487 (2017).

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017